Evogene completes phase 1 trial of bacterial cancer treatment BMC128

June 2, 2026 7:00 AM

Evogene Ltd. (NASDAQ: EVGN) announced completion of a phase 1 clinical study of BMC128, a live bacterial product developed by ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found